458 related articles for article (PubMed ID: 17995495)
21. Endometrial pathologies associated with postmenopausal tamoxifen treatment.
Cohen I
Gynecol Oncol; 2004 Aug; 94(2):256-66. PubMed ID: 15297160
[TBL] [Abstract][Full Text] [Related]
22. Tamoxifen use and endometrial lesions: hysteroscopic, histological, and immunohistochemical findings in postmenopausal women with breast cancer.
Dibi RP; Zettler CG; Pessini SA; Ayub AV; de Almeida SB; da Silveira GP
Menopause; 2009; 16(2):293-300. PubMed ID: 19034048
[TBL] [Abstract][Full Text] [Related]
23. Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine device.
Haimovich S; Checa MA; Mancebo G; Fusté P; Carreras R
Menopause; 2008; 15(5):1002-4. PubMed ID: 18451744
[TBL] [Abstract][Full Text] [Related]
24. [Levonorgestrel-releasing intrauterine device (Mirena) and breast cancer: what do we learn from literature for clinical practice?].
Boutet G
Gynecol Obstet Fertil; 2006 Nov; 34(11):1015-23. PubMed ID: 17092752
[TBL] [Abstract][Full Text] [Related]
25. Use of the levonorgestrel-releasing intrauterine system in breast cancer patients.
Trinh XB; Tjalma WA; Makar AP; Buytaert G; Weyler J; van Dam PA
Fertil Steril; 2008 Jul; 90(1):17-22. PubMed ID: 17706209
[TBL] [Abstract][Full Text] [Related]
26. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia.
Ewies AA; Alfhaily F
Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756
[TBL] [Abstract][Full Text] [Related]
27. Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial.
Gardner FJ; Konje JC; Abrams KR; Brown LJ; Khanna S; Al-Azzawi F; Bell SC; Taylor DJ
Lancet; 2000 Nov; 356(9243):1711-7. PubMed ID: 11095258
[TBL] [Abstract][Full Text] [Related]
28. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
de Jonge ET; Yigit R; Molenberghs G; Straetmans D; Ombelet W
Contraception; 2007 Aug; 76(2):91-5. PubMed ID: 17656176
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study.
Swerdlow AJ; Jones ME;
J Natl Cancer Inst; 2005 Mar; 97(5):375-84. PubMed ID: 15741574
[TBL] [Abstract][Full Text] [Related]
30. Levonorgestrel-releasing intrauterine devices.
Cohen I
Lancet; 2001 Mar; 357(9258):801. PubMed ID: 11253990
[No Abstract] [Full Text] [Related]
31. [Histological analysis of endometrial polyps in breast cancer patients treated with tamoxifen (nolvadex)].
Ivanova V; Karaivanov M; Raĭcheva S; Marinov E; Gorchev G
Akush Ginekol (Sofiia); 2004; 43(2):33-6. PubMed ID: 15185527
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial.
Alkner S; Bendahl PO; Fernö M; Nordenskjöld B; Rydén L;
Eur J Cancer; 2009 Sep; 45(14):2496-502. PubMed ID: 19535242
[TBL] [Abstract][Full Text] [Related]
33. Detection of endometrial cancer in asymptomatic postmenopausal breast cancer patient treated with tamoxifen: a case report.
Sinawat S; Chiyabutra T; Kleabkaew P
J Med Assoc Thai; 2001 Jul; 84(7):1033-6. PubMed ID: 11759963
[TBL] [Abstract][Full Text] [Related]
34. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on sexual functioning among women with menorrhagia: a 5-year randomised controlled trial.
Halmesmäki K; Hurskainen R; Teperi J; Grenman S; Kivelä A; Kujansuu E; Tuppurainen M; Yliskoski M; Vuorma S; Paavonen J
BJOG; 2007 May; 114(5):563-8. PubMed ID: 17439564
[TBL] [Abstract][Full Text] [Related]
35. Prevention of Benign Endometrial Polyp Recurrence Using a Levonorgestrel-releasing Intrauterine System in Premenopausal Patients: A Retrospective Cohort Study.
Wang Y; Yang M; Huang X; Li X; Lin E; Feng Y
J Minim Invasive Gynecol; 2020; 27(6):1281-1286. PubMed ID: 32446971
[TBL] [Abstract][Full Text] [Related]
36. The levonorgestrel-releasing intrauterine device induces endometrial decidualisation in women on tamoxifen.
Philip S; Taylor AH; Konje JC; Habiba M
J Obstet Gynaecol; 2019 Nov; 39(8):1117-1122. PubMed ID: 31195902
[TBL] [Abstract][Full Text] [Related]
37. The levonorgestrel intrauterine system is an effective treatment in women with abnormal uterine bleeding and anticoagulant therapy.
Vilos GA; Tureanu V; Garcia M; Abu-Rafea B
J Minim Invasive Gynecol; 2009; 16(4):480-4. PubMed ID: 19573825
[TBL] [Abstract][Full Text] [Related]
38. [Comparative study of the endometrial pathology using flexible ambulatory hysteroscopy of patients treated with Tamoxifen].
Kuzmanov B
Akush Ginekol (Sofiia); 2004; 43(3):32-3. PubMed ID: 15341254
[TBL] [Abstract][Full Text] [Related]
39. [Monitoring of postmenopausal women treated with tamoxifen for breast carcinoma].
Epifani S; Lattarulo S; Maiorino R; Fabiano G
G Chir; 2000; 21(6-7):310-2. PubMed ID: 10916956
[TBL] [Abstract][Full Text] [Related]
40. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts.
Reid PC; Virtanen-Kari S
BJOG; 2005 Aug; 112(8):1121-5. PubMed ID: 16045528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
